Zenith Capital Corp. (ZHCLF)

Market Cap	6.15M
Revenue (ttm)	n/a
Net Income (ttm)	-7.07M
Shares Out	153.71M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,230
Average Volume	8,930
Open	0.1000
Previous Close	0.0400
Day's Range	0.0400 - 0.1000
52-Week Range	n/a
Beta	370.67
RSI	46.02
Earnings Date	Aug 28, 2025

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. It has research and development collaboration agreement with National Cancer Institute, and licensing agreement with Newsoar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: ZHCLF